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Abstract
Background: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical 
resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for 
advanced GIST. The present study was designed to further observe the effectiveness of the imatinib mesylate 
treatment on the recurrent GIST and the correlation between the liver metastasis and the outcome.
Methods: Forty-two patients who had recurrent GIST after the first radical resection were enrolled. According to the 
recurrent sites, the patients were divided into 3 groups: group LG (recurrent liver GISTs), group AG (recurrent abdominal 
GISTs) and group ALG (recurrent abdominal and liver GISTs). All the patients were given imatinib mesylate at an initial 
dose of 400 mg per day. Their clinical data was prospectively collected. A follow-up over 3 years was conducted. Tumor 
response, time to progression and survival were evaluated.
Results: The long-term Imatinib mesylate treatment was safe and well tolerated. At a median follow-up time for 39.5 
months, the 3-year survival rate was 66.7%. Median TTP and OS were 37 months (95% CI: 28.2~45.8 months) and 48 
months (95% CI: 37.0~58.9 months), respectively. There was no statistical difference in tumor response among the 3 
groups. The similar TTP (P = 0.291) and OS (P = 0.160) were observed in the 3 groups.
Conclusions: The imatinib mesylate treatment could prolong the survival of the patients who have recurrent GIST after 
the radical surgery in spite of an existence of the liver metastasis. Survival was not significantly affected by liver 
metastasis when imatinib mesylate was warranted.
Background
Gastrointestinal stromal tumor (GIST) accounts for
approximately 1% to 3% of all the gastrointestinal tract
neoplasms and 5% to 6% of all the mesenchymal tumors
(sarcomas) [1,2]. GIST expresses mutant protein-tyrosine
kinase KIT (CD117), which results in constitutive activa-
tion of the KIT receptor tyrosine kinase [3,4].
Surgical operation, as the first-line treatment, has been
the most effective method for the resectable GIST. Most
of the chemotherapy agents and radiation have failed to
treat GIST [5]. About 80% of the patients have the tumor
recurrence or/and metastasis after the radical operation,
and the most common site of the metastasis is the liver
[6,7]. Before the imatinib mesylate was used, another
resection had to be performed to remove the relapsed
tumor when GIST recurred after the first radical surgery.
Unfortunately, the outcome was still rather poor, and the
patients could only achieve a median survival of about 15
months even if they had undergone another surgical
operation [8,9]. If the relapsed tumor could not be
removed, the patient would have a much worse progno-
sis.
Imatinib mesylate, a small-molecule orally bioavailable
drug, is able to inhibit KIT. Imatinib mesylate has proved
to be the most active agent for advanced GIST [10,11]. A
long-term follow-up phase II study on the imatinib mesy-
late treatment for the patients with advanced GIST has
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revealed a response rate of 68% and a median overall sur-
vival time of 58 months [12]. A recent study has also
proved the advantages of the adjuvant treatment with
imatinib mesylate in recurrent-free survival [13]. Not a
few patients with recurrent GIST after surgery have used
imatinib mesylate as a salvage therapy, but no sufficient
data about those patients are available. More than half of
the recurrent GIST cases have liver metastasis. Liver
involvement was always considered as a bad prognostic
factor in solid tumors, but whether liver metastasis could
influence the outcome of the recurrent GIST treated with
imatinib mesylate has not been clear yet. The present
study was focused on whether imatinib mesylate could
prolong the survival of the patients who had the recurrent
GIST after the first radical operation and whether the
liver metastasis could influence the effectiveness of ima-
tinib mesylate treatment. In order to confirm the final
outcome, we performed a long-term follow-up.
Methods
Patients
From March 2003 to June 2006, 52 patients with patho-
logically-confirmed GIST were treated with imatinib
mesylate (Glivec®, Novartis, Switzerland) in Cancer Cen-
ter of West China Hospital. This program was supported
by China Charity Federation (CCF). Each patient had
signed a writing informed consent form before the ima-
tinib mesylate treatment. Clinical data were gathered
prospectively from 42 patients who had the recurrent
GIST after the prior radical resection. No adjuvant che-
motherapy, radiation or targeted therapy had been used
for the patients. The median interval from the first sur-
gery to the later tumor progression was 15.5 months
(range, 2~108 months). According to the recurrent sites,
the 42 patients were further divided into 3 groups: the LG
group (recurrent liver GISTs) (n  = 10), the AG group
(recurrent abdominal GISTs) (n = 16) and the ALG group
(recurrent abdominal and liver GISTs) (n = 16). Details of
the patients' characteristics were listed in Table 1.
The imatinib mesylate treatment
Imatinib mesylate (Glivec®) at an initial dose of 400 mg
per day was suggested to be taken. The patients were also
advised to take this drug orally after meals. The initial
dose was used until the disease progression was detected,
the unacceptable toxicity was observed or the patient's
refusal was noted. The dose level would be upgraded to
600 mg per day or to a maximal 800 mg per day when the
tumor progression was observed.
The medical examinations and the follow-up
Before the imatinib mesylate treatment, the patients
underwent the following medical reviews: medical his-
tory collection, physical examination, evaluation of the
performance status, full hematological tests, blood bio-
chemistry (bilirubin, aspartate aminotransferase, alanine
aminotransferase, albumin, serum lactate dehydrogenase,
urea, creatinine, glucose, serum electrolytes), chest radi-
ography, and full abdomen contrast spiral computerized
tomography. During the treatment, the patients were
asked to meet their doctors once a month and the fre-
quency might be increased when they had any medical
problems. Adverse effects, drug usage and other medical
events were recorded at each of the visits. Hematological
and biochemical tests were also performed. The follow-
up was stopped only when the patient died or lost of the
contact with the doctors.
Evaluation on the response, toxicity and survival
The tumor response was evaluated every 3 months by the
contrast spiral computerized tomography as planned or
when necessary. An independent investigator was in
charge of the measurement. The tumor response was
defined according to Response Evaluation Criteria in
Solid T umors (RECIST) [14]. US National Cancer Insti-
tute Common Toxicity Criteria (NCI-CTC) version 2.0
was used to evaluate the toxicities. Time to the tumor
progression (TTP) was defined as the period from the
first dose of imatinib mesylate to the tumor progression,
and the overall survival (OS) was defined as the time
from the beginning of the imatinib mesylate treatment to
the patient's death.
Statistical analysis
The tumor response, median TTP and median OS of the
42 patients were calculated. The Chi-Square test was
used to compare the response rates among the 3 groups,
the Kaplan-Meier method and the Log-Rank test were
used to evaluate the survival. P values <0.05 were consid-
ered significantly different among the groups.
Results
The treatment exposure and the follow-up
The 42 patients with recurrent or/and metastatic GIST
after the first radical resection were treated with imatinib
mesylate at an initial dose of 400 mg per day. 11 of the
patients increased the dose level to 600 mg per day due to
the tumor progression, 3 of the patients changed to use
sunitinib because of the failure of imatinib mesylate treat-
ment. None of the 42 patients discontinued the imatinib
mesylate administration except those who experienced
tumor progression or died. Median time of the follow-up
was 39.5 months (range, 5~66 months). No patient lost
the observation. Among the patients, 26 had the tumor
progression and 21 died before the clinical data were ana-
lyzed.Zhu et al. BMC Cancer 2010, 10:199
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Toxicity
Adverse effects of imatinib mesylate were generally mild
and were well tolerated. No patient discontinued the ima-
tinib mesylate treatment because of its toxicity. The most
common hematological and non-hematological adverse
events were anemia (33.3%) and edema (59.5%), respec-
tively. Other toxicities included fatigue, nausea, rash,
neutropenia, aminopherase abnormal, vomiting, and
thrombocytopenia. Most of the adverse effects needed no
medicinal treatment. No grade 4 adverse effect or the
treatment related death occurred. Details of the adverse
effects were listed in Table 2.
Tumor response
All the 42 patients were evaluated on the tumor response
to the imatinib mesylate treatment. Among the patients
in the LG group, 1 (10%) achieved the best response as a
partial remission and 9 (90%) had a stable disease. Among
the patients in the AG group, 1 (6.3%) had a complete
remission, 4 (25%) had a partial remission, 8 (50%) had a
stable disease and 3 (18.7%) had a disease progression.
Table 1: Patients' characteristics.
Patient number (%)
Characteristic LG group AG group ALG group P value
Patient treated 10 16 16 -
Age -
Median 51.5 55 51.5
Range 27~75 23~71 34~87
Sex 0.694
Male 7(70%) 9 (56.3%) 11(68.8%)
Female 3(30%) 7 (43.7%) 5(31.2%)
Primary tumor site 0.711
Gastro 6 (60%) 9 (56.3%) 8(50%)
Small intestine 2 (20%) 4 (25%) 3(18.8%)
Colon 2 (20%) 2 (12.5%) 3(18.8%)
Rectum 0 1 (6.2%) 0
Mesentery 0 0 2(12.5%)
Recurrent-free time from surgery -
Median (month) 15.5 12 24
Range (month) 9~108 2~100 3~108
ECOG performance status 0.815
0 3 (30%) 4 (25%) 6(37.5%)
1 6(60%) 9 (56.3%) 9(56.3%)
2 1 (10%) 2 (12.5%) 0
3 0 1 (6.2%) 1(6.2%)
Biomarker
CD117 positive 10 (100%) 16 (100%) 16(100%) -
CD34 positive 7 (70%) 12 (75%) 14(87.5%) 0.518
Aggressive behavior 0.492
Very low & low risk 4(40%) 4(25%) 8(50%)
Intermediate risk 2(20%) 2(12.5%) 3(18.8%)
High risk 4(40%) 10(62.5%) 5(31.2%)
LG: Recurrent liver GISTs
AG: Recurrent abdominal GISTs
ALG: Recurrent abdominal and liver GISTsZhu et al. BMC Cancer 2010, 10:199
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Page 4 of 7
Among the patients in the ALG group, 8 (50%) had a par-
tial remission, 7 (43.8%) had a stable disease and 1 (6.3%)
had a disease progression. The tumor control rates in the
three groups were 100%, 81.3% and 93.8%, respectively.
There was no statistically significant difference in the
tumor response among the LG, the AG and the ALG
groups (10%, 31.3% and 50%, respectively, P  = 0.106).
Details of the tumor response were presented in Table 3.
Survival
At the time the analysis was performed, 26 patients had a
tumor progression and 21 patients died. Among the
enrolled 42 patients, the median TTP was 37 months
(95% CI: 28.2~45.8 months) and the median OS was 48
months (95% CI: 37.0~58.9 months). The 1-year, 2-year
and 3-year survival rates were 95.2%, 83.3% and 66.7%,
respectively. Patients in the LG group achieved the high-
est 3-year survival rate of 80% and the ALG group pre-
sented the lowest 3-year survival rate of 56.3%.
In the LG group, the median TTP was 48 months (95%
CI: unavailable) and the median OS was unavailable
because over 50% of the patients were alive. In the AG
group, the median TTP was 39 months (95% CI:
28.6~49.4 months) and the median OS was 43 months
(95% CI: unavailable). In the ALG group, the median TTP
was 33 months (95% CI: 15.4~50.6 months) and the
median OS was 39 months (95% CI: 24.4~53.6 months).
According to the results of the Log-Rank test, there was
no statistically significant difference in TTP (Fig. 1) or in
OS (Fig. 2) among the 3 groups (P = 0.291, P = 0.160,
respectively).
Discussion
G I S T  i s  t h e  m o s t  c o m m o n  s a r c o m a  o f  t h e  a l i m e n t a ry
tract that has a high resistance to chemotherapy and radi-
ation. It is now categorized as a spindle-cell or a mixed
epithelioid neoplasm located in the gastrointestinal tract,
presumably originated from the same progenitor cell with
the interstitial cells of Cajal [15]. GIST expresses a KIT
protein (CD117) as its characteristic, which establishes
the diagnosis. Surgery is always the first choice of treat-
ment for the localized, resectable GIST; unfortunately,
Table 3: Tumor response.
Response evaluation
Group CR PR SD PD Response rate P value Tumor control rate P value
L G 0190 1 0 % 1 0 0 %
A G 1483 3 1 . 3 % 0 . 1 0 6 8 1 . 3 % 0 . 2 4 3
A L G0871 5 0 % 9 3 . 8 %
CR: complete remission
PR: partial remission
SD: stable disease
PD: disease progression
Table 2: Main toxicities per patient.
T o x i c i t y G r a d e  1G r a d e  2G r a d e  3G r a d e  4
Hematological
Hemoglobin 11(26.2%) 2(4.8%) 1(2.4%) 0
Neutrophil 7(16.7%) 3(7.1%) 0 0
Platelet 2(4.8%) 0 0 0
Non-hematological
Edema 23(54.8%) 2(4.8%) 0 0
Fatigue 11(26.2%) 3(7.1%) 1(2.4%) 0
Nausea 13(30.9%) 1(2.4%) 0 -
Rash 9(21.4%) 1(2.4%) 0 0
Vomiting 3(7.1%) 0 0 0
SGOT (AST) 3(7.1%) 0 0 0
SGPT (ALT) 2(4.8%) 0 0 0Zhu et al. BMC Cancer 2010, 10:199
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half of the patients have a tumor recurrence within
months [5,16].
Liver was reported to be the most common site of the
GIST metastasis. Over 60% of the patients were found to
have a liver involvement during the disease process [6,7].
Recurrence in the primary site and/or the other sites was
also found whether or not accompanied by the liver
metastasis. The liver metastasis was always regarded as
an impressive poor prognostic factor in solid tumors, and
the patients had a short survival for several months
[17,18]. The patients with a resectable liver-metastatic
GIST had to undergo a second line localized resection or
so-called cytoreductive surgery [19]. Imatinib mesylate
was proved to have an impressive therapeutic effect on
the patients with an advanced GIST. A good 2-year sur-
vival rate of 95.2% was found in the patients who had only
a liver-metastatic GIST after the prior radical resection
combined with the treatment of imatinib mesylate [20].
However, the relationship between the liver metastasis
and the outcome of the imatinib mesylate treatment has
rarely been studied. So, the present study was focused on
whether the liver metastasis would influence the survival
of the patients who were treated with imatinib mesylate.
Although the results from our previous study answers
the above question to some extent. The present study fur-
ther proved that imatinib mesylate was able to prolong
the survival time of the patients who had suffered from
recurrent GIST after the radical surgery. Our median fol-
low-up for 39.5 months revealed that 21 patients were
still alive, with a 3-year survival rate of 66.7% and a
median overall survival of 48 months (95% CI: 37.0~58.9
months). Oral imatinib mesylate, instead of another palli-
ative surgery, was the reasonable choice for the patients
who had recurrent GISTs that can not be radically
removed. The clinical data from the patients in the LG,
the AG and the ALG group were comparable. The analy-
sis showed that the patients in the three groups had a
similar tumor-response rate, TTP and OS. In the LG
group, 7 of the 10 patients who had only liver-metastatic
GIST were still alive when the clinical data were evalu-
ated. Those patients achieved the highest 3-year survival
rate of 80% in the current study. Survival was not signifi-
cantly affected by liver metastases when imatinib mesy-
late was warranted.
Edema and anemia, although mild and well tolerated,
were the commonest adverse effects observed during this
Figure 1 Comparison of the time to progression among the three groups.Zhu et al. BMC Cancer 2010, 10:199
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long-term imatinib mesylate treatment. No treatment-
related death occurred.
Tumor's resistance to imatinib mesylate is still a major
problem. An increase of the imatinib mesylate dose to
600 mg per day or a maximal dose of 800 mg per day is
useful but its effectiveness only lasts for a short time. A
change to another targeting agent, such as sunitinib,
could improve the outcome [21]. In our study, for the eco-
nomic reason, only 12 of the 26 patients (46.2%) who had
tumor progression used an increased dose of imatinib
mesylate, only 3 patients (11.5%) were given sunitinib.
The tumor control rate achieved by the second-line ther-
apy was 23.1% in our study. The median survival time was
5 months (range, 1~23 months) after the failure of the
imatinib mesylate treatment of 400 mg per day.
Conclusions
The imatinib mesylate treatment could prolong the sur-
vival of the patients who have recurrent GIST after the
radical surgery in spite of an existence of the liver metas-
tasis. Survival was not significantly affected by liver
metastasis when imatinib mesylate was warranted.
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